

[JoC] #995 Revision required

From: Indonesian Journal of Cancer (admin@indonesianjournalofcancer.or.id)
To: haryati@ulm.ac.id; fitya.arginita@ulm.ac.id; ikaoktaviyanti@gmail.com
Date: Friday, February 17, 2023 at 10:20 AM GMT+8

Dear Haryati,

Thank you for submitting your revised manuscript entitled **"Survival of Lung Adenocarcinoma Patients with Tyrosine Kinase Inhibitor Therapy Based on EGFR Mutation Status in Tumor and Plasma Samples: Case Studies"**. The editorial team and a group of expert reviewers have assessed your submission and feel that it has a potential for publication. So we would like to invite you to revise the manuscript and resubmit for further review.


The reviewer(s) comments for the author(s), is included as an attached file to this mail. Please revise your manuscript accordingly and reply to the reviewer(s) comments in a separate file (a txt, doc, or pdf file). In the reply template file, provide details about the changes you made to the manuscript (refer to section and paragraph that you made changes in the revised manuscript).


Please upload the revised manuscript, and reply template file to the journal website by login to your account, and send the files to the email admin@indonesianjournalofcancer.or.id.

For the timely and orderly processing of your manuscript, please upload your files within 14 days from the date you receive this mail. If you need more times please send a request so that editorial staff can extend the time for you.

Once again, thank you for submitting your manuscript to this journal and we look forward to receiving your revision.

Best Regards,
Natarini
Editorial Office
Indonesian Journal of Cancer

 [JoC]1st_Review_Manuscript#995.docx
316kB

 [JoC] #995_Reply template.doc
43kB

[JJoC] Proofreading Manuscript #995

From: Indonesian Journal of Cancer (admin@indonesianjournalofcancer.or.id)

To: haryati@ulm.ac.id; fitya.arginita@ulm.ac.id; ikaoktaviyanti@gmail.com

Date: Saturday, December 9, 2023 at 02:39 PM GMT+8

Dear dr. Haryati,

Your manuscript, "**Survival of Lung Adenocarcinoma Patients with Tyrosine Kinase Inhibitor Therapy Based on EGFR Mutation Status in Tumor and Plasma Samples**" is in the final publication stage.

Herewith enclosed is the Editorial proofreading of your manuscript. Please read through the document and let us know if any correction needs to be made (including the author's names, affiliations, titles, tables, figures, citations, references, and typos).

Note: Please highlight the changes to your manuscript within the document using the track changes mode in MS Word or using bold or colored text.

Because we are trying to facilitate timely publication, we ask you to submit the final revision of your manuscript within 3 days after you receive this email.

Thank you and we look forward to receiving your revision.

Sincerely,

Adhitya Bayu Perdana
Managing Editor
Indonesian Journal of Cancer



[JJoC] Proofreading Manuscript #995 (Research Article).docx
98.2kB